Systemic sclerosis (SSC)

This early-stage trial tests whether a type of immunotherapy called CAR-T cells can safely treat children with severe systemic sclerosis, a rare autoimmune disease that causes skin thickening and organ damage. The treatment involves collecting the child's own immune cells, engine…

This Phase 2 trial tests a drug called tibulizumab in 80 adults with systemic sclerosis, a disease that causes skin thickening and can damage organs. Participants first receive either the drug or a placebo for 24 weeks, then everyone who continues gets the drug for another 28 wee…

This early-phase trial tests a new cell therapy called BEN301 for several autoimmune diseases, including scleroderma and rheumatoid arthritis. The therapy uses specially engineered immune cells (CAR-Treg cells) to calm the overactive immune system. The study involves 24 adults an…

This early-phase study tests a new treatment called Prula-cel for people with autoimmune diseases like lupus, scleroderma, and vasculitis. Prula-cel uses donor immune cells engineered to target and destroy faulty immune cells that attack the body. The goal is to find a safe dose …

This study was designed to test a new treatment for people with autoimmune diseases like lupus, scleroderma, and myositis. It combined a specially engineered immune cell product (CLBR001) with a targeted antibody drug (SWI019), with or without a preparatory chemotherapy step. How…

This pilot study tests whether a personalized online occupational therapy program is feasible and helpful for adults with scleroderma. Twenty-four participants in Spain will either receive eight online therapy sessions over four weeks plus usual care, or usual care alone. The stu…

This study will use a special blood test called mass spectrometry to look at immune cells in 500 people with various autoimmune diseases and healthy volunteers. The goal is to find patterns that could help doctors diagnose these conditions sooner. No treatments are being tested; …

This study aims to see if a questionnaire called HDISS-DU, which measures hand disability caused by digital ulcers in people with systemic sclerosis (scleroderma), is valid and reliable in Turkish. About 72 adults with scleroderma will fill out the questionnaire along with other …

This study checks if a questionnaire called the Hand ScleroDerma Lived Experience Scale (HAnDE Scale) works well for Turkish-speaking people with systemic sclerosis. Researchers will ask 54 participants to fill out the survey and perform hand movement tests. The goal is to make s…